Literature DB >> 31361382

Safety and efficacy of emicizumab and other novel agents in newborns and infants.

Glenn F Pierce1, Daniel P Hart1,2,3, Radoslaw Kaczmarek1,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31361382     DOI： 10.1111/hae.13822

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  6 in total

1.  Making friends out of foes: novel therapeutic approaches for haemophilia.

Authors:  Catriona Mactier; Cedric Hermans
Journal:  Blood Transfus       Date:  2020-12-23       Impact factor: 3.443

Review 2.  A Molecular Revolution in the Treatment of Hemophilia.

Authors:  John S S Butterfield; Kerry M Hege; Roland W Herzog; Radoslaw Kaczmarek
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

3.  Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.

Authors:  Flora Peyvandi; Johnny N Mahlangu; Steven W Pipe; Charles R M Hay; Glenn F Pierce; Peter Kuebler; Rebecca Kruse-Jarres; Midori Shima
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

4.  Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus.

Authors:  Antonio Coppola; Massimo Franchini; Giovanni Pappagallo; Alessandra Borchiellini; Raimondo De Cristofaro; Angelo Claudio Molinari; Rita Carlotta Santoro; Cristina Santoro; Annarita Tagliaferri
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241

Review 5.  Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives.

Authors:  Samantha Pasca
Journal:  J Blood Med       Date:  2022-04-16

6.  European principles of inhibitor management in patients with haemophilia: implications of new treatment options.

Authors:  C Hermans; P L F Giangrande; B O'Mahony; P de Kleijn; M Bedford; A Batorova; J Blatný; K Jansone
Journal:  Orphanet J Rare Dis       Date:  2020-08-24       Impact factor: 4.123
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.